Results for Financial Results for Quarter and Financial Year ended March 31, 2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Parmax Pharma reported deeply negative results for FY26. Revenue from operations collapsed to ₹1,211.16 lakhs from ₹2,820.40 lakhs in FY25 — a drop of about 57%. The company posted a net loss of ₹415.91 lakhs for FY26, nearly double the ₹209.40 lakh loss last year. Loss before tax widened to ₹584.57 lakhs, and basic EPS worsened to ₹(11.12) from ₹(5.60). The auditor flagged several key audit matters including an unsettled insurance claim of ₹350.57 lakhs from a 2023 fire, mutual fund investments held in the Managing Director's name in violation of Section 187(1) of the Companies Act, non-provision of depreciation on certain plants, employee benefits recorded on cash basis instead of accrual, and acceptance of ₹61.17 lakhs in deposits from an LLP in violation of RBI rules and the Companies Act.
Shareholders should be alarmed by a negative net worth of ₹614.78 lakhs (equity fully eroded), rising long-term borrowings to ₹1,151.82 lakhs, and negative operating cash flow of ₹235.54 lakhs — all pointing to serious going-concern risk. The combination of plunging revenues, widening losses, unresolved insurance recovery, and multiple compliance violations is likely to weigh heavily on the stock.